Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: No additional benefit of combination with lamivudine

Liver International

Volumn 26, Issue 4, 2006, Pages 399-405

  van Zonneveld, Monika ^a   Zondervan, Pieter E ^a   Cakaloglu, Yilmaz ^b   Simon, Christopher ^c   Akarca, Ulus S ^d   So, Thomas M K ^e   Flink, Hajo J ^a   de Man, Robert A ^a   Schalm, Solko W ^a   Janssen, Harry L A ^a   Niesters, H G M ^a   Hansen, B ^a   Vroom, B C M ^f   van Nieuwkerk, C M J ^g   de Vries, R A ^h   Jansen, J ⁱ   Drenth, J ⁱ   van den Hazel, S J ⁱ   den Ouden Muller, J W ^j   Tan, A C ^k   Adler, D M ^l   Michielsen, P ^m   van Vlierberghe, H ⁿ   Nevens, F ^o   Delwaide, J ^p   Henrion, J ^q   Zeuzem, S ^r   Gerken, G ^s   Bein, S ^s   Treichel, U ^s   Trojan, J ^t   Manns, M P ^u   Hadem, J ^u   Niederau, J ^v   Buhl, M R ^w   Hansen, I M ^w   Krogsgaard, K ^x   Cianciara, J ^y   Jablonska, J ^y   Kozlowska, J ^y   Prokopowicz, D ^z   Flisiak, R ^z   Mach, T ^aa   Buti, M ^ab   Valdes, A ^ab   Esteban, R ^ab   Rodriguez, M ^ac   Garcia Espiga, M ^ac   Andriulli, A ^ad   Stornaiulo, G ^ad   Gaeta, G B ^ad   Montalto, G ^ae   D'Antona, F ^ae   Kitis, G E ^af   Xiarchos Panagiotis, P ^af   Tassopoulos, N C ^ag   Ersoz G ^d   Karayalcin, S ^ah   Yurdayin, C ^ah   Bozkaya, H ^ah   Simsek, H ^ai   Balaban, Y ^ai   Senturk, H ^aj   Tabak, F ^aj   Lurie, Y ^ak   Heathcote, J ^al   Feinman, S V ^am   Greenbloom, S ^an   Sulaiman, D A ^ao   Guan, R ^ap   Merican, I ^aq   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ISTANBUL UNIVERSITY   (Turkey)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^e PRINCESS MARGARET HOSPITAL   (Hong Kong)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h RIJNSTATE HOSPITAL   (Netherlands)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j SINT FRANCISCUS GASTHUIS   (Netherlands)

^k CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^l ERASME HOSPITAL   (Belgium)

^m ANTWERP UNIVERSITY HOSPITAL   (Belgium)

ⁿ GHENT UNIVERSITY HOSPITAL   (Belgium)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^p UNIVERSITY OF LIÈGE   (Belgium)

^q Hospital de Jolimont   (Belgium)

^r SAARLAND UNIVERSITY   (Germany)

^s UNIVERSITY HOSPITAL ESSEN   (Germany)

^t GOETHE UNIVERSITY   (Germany)

^u HANNOVER MEDICAL SCHOOL   (Germany)

^v St Marien Hosp Oberhausen O   (Germany)

^w AARHUS UNIVERSITY HOSPITAL   (Denmark)

^x HVIDOVRE HOSPITAL   (Denmark)

^y MEDICAL UNIVERSITY OF WARSAW   (Poland)

^z MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^aa JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^ab HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^ac HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^ad Clinica Malattie Infettive   (Italy)

^ae UNIVERSITY OF PALERMO   (Italy)

^af General Regional Hospital George Papanikolaou   (Greece)

^ag West Attica Hospital   (Greece)

^ah ANKARA UNIVERSITY   (Turkey)

^ai HACETTEPE UNIVERSITY   (Turkey)

^aj ISTANBUL UNIVERSITY   (Turkey)

^ak Department of Otolaryngology Head and Neck Surgery   (Israel)

^al TORONTO WESTERN HOSPITAL   (Canada)

^am MOUNT SINAI HOSPITAL   (Canada)

^an General Hospital Etobicoke   (Canada)

^ao CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^ap MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

^aq INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

more..

Author keywords

Fibrosis; HBV; Liver inflammation; Pegylated interferon; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2B; PLACEBO;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

EID: 33645730480     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01257.x     Document Type: Article

References (16)

1. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339 (2): 61-8.
2. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341 (17): 1256-63.
3. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000; 46 (4): 562-8.
4. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The hepatitis interventional therapy group. N Engl J Med 1990; 323 (5): 295-301.
5. Janssen HL, Gerken G, Carreno V, et al. Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999; 30 (1): 238-43.
6. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334 (22): 1422-7.
7. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39 (3): 804-10.
8. Janssen HLA, van Zonneveld M, Senturk H, et al. Pegylated interferon alpha-2b alone or in combination with lamivudine as treatment for HBeAg-positive chronic hepatitis B. Lancet 2005; 365: 123-9.
9. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a HBeAg-positive chronic hepatitis B study group. peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352 (26): 2682-95.
10. Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95 (5): 1318-25.
11. Saracco G, Mazzella G, Rosina F, et al. A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. Hepatology 1989; 10 (3): 336-41.
12. Krogsgaard K, Marcellin P, Trepo C, et al. Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group. J Hepatol 1996; 25 (6): 803-13.
13. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124 (1): 105-17.
14. Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32 (4 Part 1): 828-34.
15. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36 (6): 687-96.
16. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125 (6): 1714-22.